candesartan has been researched along with Liver Cirrhosis in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg-1·day-1) intraperitoneally for 2 weeks." | 7.85 | Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. ( Ali, SS; Gazzaz, ZJ; Ibraheem, MS; Murad, HA, 2017) |
| " Low-grade chronic liver failure (CLF) was induced in 3-month old Sprague-Dawley male rats using thioacetamide (TAA, 50 mg·kg-1·day-1) intraperitoneally for 2 weeks." | 3.85 | Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats. ( Ali, SS; Gazzaz, ZJ; Ibraheem, MS; Murad, HA, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Murad, HA | 1 |
| Gazzaz, ZJ | 1 |
| Ali, SS | 1 |
| Ibraheem, MS | 1 |
| Kim, JH | 1 |
| Kim, JM | 1 |
| Cho, YZ | 1 |
| Na, JH | 1 |
| Kim, HS | 1 |
| Kim, HA | 1 |
| Kang, HW | 1 |
| Baik, SK | 1 |
| Kwon, SO | 1 |
| Cha, SH | 1 |
| Kim, YJ | 1 |
| Kim, MY | 1 |
| Nie, L | 1 |
| Imamura, M | 1 |
| Itoh, H | 1 |
| Ueno, H | 1 |
| Castano, GO | 1 |
| Sookoian, SC | 1 |
| Heim, MH | 1 |
| Jacob, L | 1 |
| Beglinger, C | 1 |
2 trials available for candesartan and Liver Cirrhosis
| Article | Year |
|---|---|
Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2014 |
The angiotensin II receptor antagonist candesartan is not effective in reducing portal hypertension in patients with cirrhosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hyperte | 2007 |
3 other studies available for candesartan and Liver Cirrhosis
| Article | Year |
|---|---|
Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats.
Topics: Alanine Transaminase; Ammonia; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Bip | 2017 |
Pitavastatin enhances the anti-fibrogenesis effects of candesartan, an angiotensin II receptor blocker, on CCl4-induced liver fibrosis in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihype | 2004 |
Angiotensin II type 1 receptor blockade in early cirrhosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compounds; Humans; Liv | 2007 |